Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous interferon beta-1a tolerance induction in multiple sclerosis patients with neutralizing antibodies
2008-000256-26Phase 2Terminated
- Sponsor
- Queen Mary University of London
- Start
- Dec 2010
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of interferon beta-1a and mitoxantrone in multiple sclerosis (MS), sponsored by Queen Mary University of London. Primary endpoint: Safety and immunological effects of high-dose intravenous interferon beta-1a after transient leukocyte depletion with mitoxantrone. Started Dec 2010; status: terminated.
02
Drugs
interferon beta-1amitoxantrone
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2008-000256-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000256-26.